SS
INZY

Steve Schonfeld’s Inozyme Pharma INZY Stock Holding History

Steve Schonfeld’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-74,800
Closed -$573K – 2345
2024
Q1 		$573K Sell
74,800
-33,900
-31% -$186K ﹤0.01% 1430
2023
Q4 		$463K Sell
108,700
-203,180
-65% -$722K ﹤0.01% 1310
2023
Q3 		$1.31M Buy
311,880
+242,080
+347% +$1.23M 0.01% 933
2023
Q2 		$389K Buy
69,800
+41,200
+144% +$244K ﹤0.01% 1309
2023
Q1 		$164K Buy
+28,600
New +$75.6K ﹤0.01% 1587

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Steve Schonfeld's INZY Position: Q2 2024 in Review

Steve Schonfeld sold out of Inozyme Pharma (INZY) in Q2 2024, closing a stake of 74,800 shares — an estimated $573K sold.

Steve Schonfeld first reported a position in INZY in Q1 2023 and held it in 5 quarters. The position peaked at $1.31M in Q3 2023. 90 funds tracked by Wall St. Rank hold INZY as of Q2 2024.

  • Steve Schonfeld reported no remaining Inozyme Pharma position as of Q2 2024 after selling out during the quarter.
  • Steve Schonfeld sold 74,800 Inozyme Pharma shares in Q2 2024, an estimated $573K.
  • Steve Schonfeld first reported a position in Inozyme Pharma in Q1 2023 and held it in 5 quarters.
  • Steve Schonfeld's Inozyme Pharma position peaked at $1.31M in Q3 2023.
  • 90 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.